About bimekizumab
Interleukin-17A and interleukin-17F inhibitor
Used for
- Moderate-to-severe plaque psoriasis in adults
- Active psoriatic arthritis in adults
- Active axial spondyloarthritis in adults
- Hidradenitis suppurativa in adults
Usual adult dose
Usually 320 mg under the skin every four weeks initially for psoriasis or hidradenitis; maintenance schedules vary by condition and response.
Common side effects
- Upper respiratory infections
- Oral thrush and other fungal infections
- Headache
- Injection-site reactions
Important warnings
- Do not start during an active serious infection.
- Screen for tuberculosis before treatment; monitor for infection.
- Avoid live vaccines during treatment.
- May worsen inflammatory bowel disease; report persistent bowel symptoms.
Pregnancy
Human pregnancy information is limited; use only when clearly needed after weighing potential risks.
Breastfeeding
Unknown whether it enters breast milk; consider treatment benefits and infant risks.
Interactions
- Live vaccines may cause infection; avoid during treatment.
- Other biologic immunosuppressants may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.